22 results about "Phosphoprotein" patented technology

The application provides a kind of double ligand HOF functionalized magnetic nanomaterial and its preparation method and application, belongs to functionalized magnetic material preparation technical field.The method first synthesizes Fe3O4NPs, NH3·H2O is added to solution to be alkaline, then the temperature is heated to react, obtains Fe3O4NPs suspension liquid;Fe3O4NPs suspension liquid is added to oleic acid stirring, and the obtained Fe3O4@OA;Guanidine hydrochloride monomer is dissolved in solvent, then Fe3O4@OA is dispersed in stirring, and Fe3O4@GD is obtained;Finally, Fe3O4@GD is mixed with GD, boric acid, triethylamine and 1,2,4-trichlorobenzene containing solution stirring, and double ligand HOF functionalized magnetic nanomaterial is obtained.The functional material of the application can also effectively capture glycoprotein, and identify glycoprotein and phosphoprotein.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV. Also provided is the use of a HEK293 cell line or a HEK293 cell line adapted to suspension growth for rescue of Vesicular Stomatitis Virus (VSV) or the use of a plasmid encoding SV40 Large T antigen for rescue of Vesicular Stomatitis Virus (VSV) in a HEK293 cell line or a HEK293 cell line adapted to suspension growth HEK293-F cells by means of transient transfection.

To reduce the amount or activity of PLN RNA in cells or animals, in certain cases, oligomeric compounds, methods, and pharmaceutical compositions are provided for reducing the amount of phospholamban protein in cells or animals. Such oligomeric compounds, methods, and pharmaceutical compositions are useful for treating cardiomyopathy, heart failure, or arrhythmias.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The present invention relates to a gene construct comprising a nucleotide encoding a decoy peptide that inhibits dephosphorylation of a protein phosphatase 1 (PP1)-mediated phosphoprotein (PLB) and a nucleotide encoding a CCN5 protein or a fragment thereof; the invention also relates to a pharmaceutical composition for preventing and treating heart diseases. The pharmaceutical composition comprises the gene construct. The pharmaceutical composition for preventing and treating heart diseases according to the present invention simultaneously expresses a decoy peptide that inhibits PP1-mediated dephosphorylation and a CCN5 protein, thereby exhibiting a synergistic therapeutic effect, and thus can be effectively used for preventing or treating heart diseases.

The invention discloses an N-acetylglucosamine transferase mutant and application thereof in production of L-tryptophan, and belongs to the technical field of genetic engineering. In order to solve the problems of yield limitation and the like caused by excessive consumption of phosphoenolpyruvic acid in the production of L-tryptophan, the invention weakens a phosphoprotein coding gene crr on escherichia coli; meanwhile, a uridine diphosphate galactose pyranose mutase gene glf and a glucokinase gene glk of the pseudomonas mobilis and an endogenous galactose H (+) transporter enzyme gene galP of escherichia coli are integrated at a pflB site, and a genetically engineered bacterium is obtained; mutagenesis is carried out on the basis to obtain a mutant strain with improved L-tryptophan yield; and the N-acetylglucosamine transferase mutants nagC and nagE are obtained by virtue of sequencing. Fermentation proves that overexpression of the mutant nagC or nagE or simultaneous overexpression of the mutants nagC and nagE in the genetically engineered bacteria can improve the yield of L-tryptophan.

The invention discloses selenium-containing bioglass, preparation thereof and application of the selenium-containing bioglass in a pulp covering material for repairing dental pulp injury, or application of the selenium-containing bioglass in expression promoters of RUNX transcription factor 2, dentin saliva phosphoprotein and dentin matrix acid phosphoprotein 1. The preparation method comprises the following steps: preparing Se-Ca-Si-P quaternary system sol by adopting a sol-gel method, sealing and aging at room temperature until the sol is gel-shaped, and drying; and grinding the dried product, calcining, carrying out secondary grinding on the calcined powder, and screening to obtain the selenium-containing bioglass. The material not only can rapidly induce bone-like apatite deposition, has excellent antioxidant and antibacterial activity, but also can remarkably promote proliferation and migration of dental pulp stem cells, effectively up-regulate expression of a dental differentiation gene RUNX transcription factor 2, dentin saliva phosphoprotein and dentin matrix acid phosphoprotein 1, and can promote the growth of dental pulp stem cells. The material can be used as a pulp capping material in the aspects of dental pulp injury repair, dentin regeneration and the like.

The present invention relates to a polypeptide composition comprising a nucleic acid encoding a mutated pp65 polypeptide, the nucleic acid being mRNA, viral RNA or replicon RNA, said composition being capable of expressing the mutated pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, producing effector cells and specific antibodies having a tumor cell killing effect.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The application discloses a vascular expansion stimulating phosphoprotein specific monoclonal antibody and application. In the monoclonal antibody, the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody only recognizes VASP, and does not exist cross reaction with EVL and Mena in the same family, and the antibody can recognize all isomers of VASP, and can recognize phosphorylated and non-phosphorylated VASP.

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of phospholamban protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The present invention provides methods and compositions comprising a C-terminal fragment of the Astrocytic phosphoprotein (PEA-15) protein in the treatment and / or prevention of a disorder or a disease Preferably, the disorder or a disease is a neurodevelopmental, a neurological or a psychiatric disorder or disease.

The invention discloses carbon dot / calcium phosphate composite bone glue with high shear strength and active oxygen scavenging capacity and a preparation method thereof, and relates to the carbon dot / calcium phosphate composite bone glue and the preparation method thereof. The invention aims to solve the problems of low shear strength and lack of active oxygen scavenging ability of calcium phosphate bone glue in the prior art. The carbon dot / calcium phosphate composite bone glue with high shear strength and active oxygen scavenging capacity is composed of calcium phosphate, acidic calcium phosphoprotein and carbon dots with active oxygen scavenging capacity, wherein the content of the carbon dots with active oxygen scavenging capacity is 0.01-10.00 wt%. The invention belongs to the technical field of calcium phosphate-based bone tissue binders.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a low-potassium low-phosphorus protein component for special medical purposes and a preparation method thereof. The protein component is of a liquid ready-to-use type, and comprises the following components on the basis of 100 mL of total volume: 10.0-12.0 g of separated whey protein powder; and 0.05 to 0.15 g of stevioside. 0.20 to 0.30 g of a compound stabilizer; and the balance of water. The compound stabilizer is prepared from phospholipid and xanthan gum. The separated whey protein powder with low phosphorus and potassium content and specific calcium content is selected as a core protein source, so that the final product has extremely low phosphorus-protein ratio and potassium content. The phosphorus intake brought by the product is obviously lower than that of commercially available like products, and the kidney metabolism burden and the hyperphosphatemia risk of patients are greatly relieved. The phospholipid and the xanthan gum in a specific mass ratio are used as a compound stabilizer, and the phospholipid is used as an emulsifier, so that protein particles can be effectively wrapped, and aggregation is prevented.

The invention provides ultra-stable nano amorphous calcium phosphate and a preparation method thereof. A phosphate radical source of the amorphous calcium phosphate is adenosine triphosphate or pyrophosphate. The amorphous calcium phosphate contains alkaline phosphatase capable of hydrolyzing adenosine triphosphate, extracellular nucleotide pyrophosphatase 1 and alpha2-HS glycoprotein or secretory phosphoprotein 1 capable of stably adsorbing calcium ions. Researches prove that a mineralization raw material adenosine triphosphate involved in the mineralization process of a human body growth plate is used as a source of phosphate radicals, and protein capable of hydrolyzing adenosine triphosphate and pyrophosphate is sequentially added and combined with protein capable of adsorbing calcium ions, so that a spherical amorphous calcium phosphate cluster structure can be formed; and the formed amorphous calcium phosphate can stably exist for more than 35 days under the conditions that the pH is 7.0-7.3 and the temperature is 37 DEG C, and can stably exist for more than 120 days under the condition of 4 DEG C, so that the stabilization time of the nanoscale amorphous calcium phosphate under the mild condition is remarkably prolonged, and the method has a wide application prospect in the field of bone tissue engineering.

The invention provides a bovine lactoferrin-phosvitin compound and a preparation method thereof. The phosvitin provided by the invention contains a large amount of phosphorylated serine, so that the phosvitin has relatively high negative charges, and forms a compound with a structure taking LF as a core and PSV as a shell with bovine lactoferrin through the synergistic effect of electrostatic interaction and hydrogen-bond interaction, so that the stability coefficient of the phosvitin is increased, the denaturation temperature is increased by 1-16 DEG C, and the denaturation time is shortened by 1-16 DEG C; the adverse effect of heat treatment on the lactoferrin is reduced, the heat stability of the lactoferrin is enhanced, the oxidation resistance is not affected, and the application range of the lactoferrin is expanded.